Facebook Linkedin RSS Twitter Youtube
Home 2024

Eli Lilly and Company

Alzheimer’s Drug Shows Slower Cognitive Decline in Lower Tau Patients
Drug Discovery

Alzheimer’s Drug Shows Slower Cognitive Decline in Lower Tau Patients

StockWatch: Investors Hammer Lilly as GLP-1 Sales Miss Forecasts
Drug Discovery

StockWatch: Investors Hammer Lilly as GLP-1 Sales Miss Forecasts

StockWatch: BioAge, Orum Reflect Renewed Interest in IPOs
Drug Discovery

StockWatch: BioAge, Orum Reflect Renewed Interest in IPOs

StockWatch: Athira Pays Price as Alzheimer’s Candidate Fails Trial
Drug Discovery

StockWatch: Athira Pays Price as Alzheimer’s Candidate Fails Trial

HAYA, Lilly Launch Up-to-$1B Metabolic Collaboration
Drug Discovery

HAYA, Lilly Launch Up-to-$1B Metabolic Collaboration

StockWatch: Lilly Narrows GLP-1 Revenue Gap with Novo Nordisk
Drug Discovery

StockWatch: Lilly Narrows GLP-1 Revenue Gap with Novo Nordisk

StockWatch: Cognition Stays the Course as Shares Plunge on Alzheimer’s Data
Drug Discovery

StockWatch: Cognition Stays the Course as Shares Plunge on Alzheimer’s Data

Lilly to Acquire Morphic for $3.2B, Adding Phase II IBD Programs
Drug Discovery

Lilly to Acquire Morphic for $3.2B, Adding Phase II IBD Programs

FDA Approves Lilly’s Amyloid-Targeting Kisunla for Early Alzheimer’s
Drug Discovery

FDA Approves Lilly’s Amyloid-Targeting Kisunla for Early Alzheimer’s

Novo Nordisk Plans $4.1B Fill-Finish Plant at Clayton, NC, Campus
Bioprocessing

Novo Nordisk Plans $4.1B Fill-Finish Plant at Clayton, NC, Campus

123...9Page 1 of 9
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.